medigraphic.com
ISSN 1561-3070 (Electronic)

2020, Number 1

<< Back Next >>

Rev Cub Oftal 2020; 33 (1)

Ocular damage in graft-versus-host disease

Castillo PAC, Noriega MJL, Benítez MMC, López HS, Casas AX, Mejía CN

Language: Spanish
References: 25
Page: 1-12
PDF size: 338.18 Kb.


ABSTRACT

Allogeneic transplantation of hematopoietic precursors is indicated in the treatment of various blood disorders, particularly malignant neoplasms. Graft-versus-host disease is the main complication of allogeneic transplants of hematopoietic organs. GVHD is an immunological condition caused by the interaction between the donor and the recipient manifested as innate and adaptive responses. It very often affects the skin and the gastrointestinal system. A variety of ocular manifestations may also occur, the most common of which are ocular surface alterations. Changes in the ocular surface may cause blindness. Early diagnosis and treatment improve prognosis. Besides the general treatment of the disease it is necessary to implement specific measures to control ocular alterations. A review was conducted of published papers on the topic to become acquainted with graft-versus-host disease and the ocular damage it causes.


REFERENCES

  1. Siegel RL. Cancer statistics. Canc J Clin. 2016;(66):7-30.

  2. Raja H, Nau CHB, Shen JF, Balasubramaniam SC, Schornack MM. Ocular graft-versus-host disease: A review. Eye Cont Lens. 2015;(5):256-61.

  3. Gale RP, Champling RE. Role of marrow transplantation in the treatment of hematologic malignancies and solid tumors. Critical review of syngeneic autologous and allogeneic transplants. Cancer Treat Rep. 1984;(68):145-61.

  4. Weidsdorf D. Gvhd the nuts and bolts. Soc Hematol Educ Program. 2007;(2):62-7.

  5. Antin JH, Ferrara JL. The pathopshysiology of graft versus host disease in hematopoietic cell trasplantation. Oxford, UK: Wiley-Blackwell. 1999;(2):5305-15.

  6. Runaas L, Magenau J, Reddy P. Advances in understanding the pathogenesis of graft-versus host disease. Michigan: University of Michigan; 2015.

  7. Arora R. Chronic gvhd risk score, a center for international blood and marrow trasplantation research analysis. Blood. 2011;(117):6714-20.

  8. Dustin ML. Role of adhesión molecules in activation signaling in t lymphocites. J Clin Immunol. 2001;(21):258-63.

  9. Reza D, Shikari H, Antin JH. Ocular graft versus host disease. Surv Ophthalmol. 2013;(3):233-51.

  10. Kennedy B, Vogesland GB, Lee L. Pathogenesis and treatment of graft versus host disease after bonemarrow trasplant. Ann Rev Med. 2003;(54):29-52.

  11. Boyer O, Cooke KR. An experimental model of idiopatic pneumonia síndrome after bone marrow trasplantation. Blood. 1996;(2):3230-9.

  12. Sánchez-Guijo F, Castilla C, Pérez-Simón JA. Oral beclomethasone dipropionate for the treatment of gastrointestinal acute graft-versus-host disease. Biol Blood Marrow Transplant. 2006;(9):936-41.

  13. Xihui L, Harrison DC. Ocular manifestations of graft versus host disease: 10 years experience. Clin Ophthalmol. 2015;(9):1209-13.

  14. Ogawa Y, Kuwana M. Dry eye as a major complication associated with chronic graft versus host disease after hematopoietic stem cell trasplantation. Cornea. 2003;(7):19-27.

  15. Jagasia M, Greinix H, Arora M. National Institutes of Health consens development project on criteria for clinical trials in chronic graft versus host disease: the 2014 Diagnosis and Staging Working Group Report. Biol Blood Marrow Transplant. 2015;21(3):389-401.

  16. Dietrich-Ntoukas T; Steven P. Ocular graft versus host disease. Ophthalmologe. 2015;(12):1027-40.

  17. Strouthidis NG; Francis PJ. Posterior complications of graft versus host disease after bone marrow trasplantation. BMJ. 2003;(11):1421-3.

  18. Pavletic S, Filipovich AH, Weisdorf D. National Institutes of Health consensus dvelopment project on criteria for clinical trails in chronic graft-versus-host-disease. Biol Blood marrow Trasplant. 2005;(11):645-56.

  19. Auw-Haedrich C, Postch C, Bohringer D, Mittelviefhaus H, Maier P, Reinhard T, Freudenberg N, Finke J, Coupland SE. Histological and immunohistochemical characterisation of conjunctival grasf versus host disease following hematopoietic stem cell trasplantation. Grafes Arch Clin Exp ophthalmol; 2007;(7):1001-7.

  20. Diez-campelo M, Martino R, Pérez RL, Pérez-simon JA. Limbus damage in ocular graft versus host disease. Nam J. 2011;(17):270-3.

  21. Lemp MA. Report of the national eye institute/industry workshop on clinical trials in dry eyes. CLAO J. 1995;(21):221-32.

  22. Rivas L, Martínez Garchitorena J, López-García JS, García Lozano I. Aplicaciones del suero autólogo en Oftalmología. Arch Soc Esp Oftalmol. 2007;(82):9-20.

  23. Dastjerdi MH, Okanobo A, Chauhan SL. Efficacy of topocal blockade of interleukin-1 in experimental dry eye disease. Am J Ophthalmol. 2012;(1):63-71.

  24. Wu M, Takahide K, Parjer PM. Use of fluid-ventilated-gas-permeable scleral lens for management of severe keratoconjunctivitis sicca secondary to chronic graft versus host disease. Biol Blood Marrow Raspl. 2007;(13):1016-21.

  25. Inoue K, Amano S, Oshika T, Tsuru T. Risk factors for corneal graft failure and rejection in penetrating keratoplasty. Acta Ophthalmol Scand. 2001;79:251-5.




2020     |     www.medigraphic.com